Detalhe da pesquisa
1.
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading.
Mol Cancer Ther
; 2024 Apr 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38641404
2.
Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein.
J Med Chem
; 67(6): 4936-4949, 2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38477582
3.
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer.
Cancer Discov
; 13(11): 2412-2431, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37552839
4.
Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5â¢MTA Complex for the Treatment of MTAP-Deleted Cancers.
J Med Chem
; 65(3): 1749-1766, 2022 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35041419
5.
Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction.
J Med Chem
; 65(14): 9678-9690, 2022 07 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35833726
6.
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor.
Nat Med
; 28(10): 2171-2182, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36216931
7.
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor.
J Med Chem
; 65(4): 3123-3133, 2022 02 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34889605
8.
The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy.
Mol Cancer Ther
; 20(6): 975-985, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33722854
9.
Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer.
J Med Chem
; 63(13): 6679-6693, 2020 07 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32250617
10.
The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.
Cancer Discov
; 10(1): 54-71, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31658955
11.
Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity.
ACS Med Chem Lett
; 9(12): 1230-1234, 2018 Dec 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30613331